NRC logo

NRC HEALTH

NRCNASDAQ
πŸ† #3090 by market capUS Equity
$767.15β–² $46.41 (+6.05%)
Simulated price
πŸ””
Track NRC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 6.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$433M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-0.2%
Declining
πŸ“ŠGross Margin
61.8%
High
πŸ’΅FCF Margin
15.5%
Healthy
βš–οΈP/S Ratio
3.1x
Fair
Otter Score
68
Fair
No chart data available for NRC.

Trading Snapshot

Day Range
$757.02 – $778.97
52-Week Range
$11.01 – $23.68
Volume
$2.73B
Avg Volume
$2.04B
Shares Outstanding
22.1M
Next Earnings
Nov 27, 2026

Fundamentals Snapshot

Annual Revenue
$137M
Last Q Revenue
$35M
P/E Ratio
73.9
P/S Ratio
3.1x
EPS (TTM)
$0.27
Dividend Yield
2.94%
Dilution (1yr)
βˆ’6.7%

Why Investors Own NRC

  • βœ“High-growth profile β€” revenue up +4.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 6% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NRC logo

NRC HEALTH

NRC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$137Mβ–Ό βˆ’4.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
56.3%β–Ό βˆ’6.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$23Mβ–Ό βˆ’35.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$16Mβ–Ό βˆ’17.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
21.8Mβ–Ό βˆ’6.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$75Mβ–Ό βˆ’$15M YoY
StockOtter Β· stockotter.space

About NRC HEALTH

National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$939.37
β–² +22.4% Upside
High Target$1,125.63
Low Target$799.67
Based on 31 analysts

Latest News & Updates